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FIGURE 1. Histiocyte showing phagocytosis of numerous erythrocytes. Color image is
available online only at www.psychopharmacology.com.

The patient received only supportive
care during his admission. Interestingly,
halving of ferritin levels was observed in
1 day after cessation of lamotrigine, which
corresponds to the half-life of ferritin,5
clearly supporting HLH as serious adverse
event of lamotrigine. Venlafaxine was restarted
on the second day after admission. Six days after admission, the patient had made a full clinical
recovery, and his biochemical parameters had
largely normalized and continued to do so during the next few weeks of outpatient follow-up.
Hemophagocytic lymphohistiocytosis
has sporadically been described after initiation of lamotrigine. With an increasing
number of reports surfacing in recent years,
the association with this nontrivial condition is becoming more clear.6–11 Nevertheless, only a handful of detailed reports are
currently available in the literature. Such
scarcity provides little guidance to the clinician confronted with this adverse event
when it comes to treatment decisions. For
example, our report indicates that early cessation of the drug enables patients to make a
full recovery without treatment and that disease markers fall very quickly upon cessation of lamotrigine. Such observations may
help forestall aggressive treatment of the
HLH where this is not strictly necessary.
Antiepileptic drugs are known to
modulate immune system activity and alter
the production of cytokines. Through these
mechanisms, immunogenic adverse effects
have been well documented for this class of
drugs, although newer agents have been less
extensively described.12 Therefore, reports
like this one should prompt clinicians to close
monitoring of the patient in the weeks after
the first prescription of lamotrigine or other
antiepileptic drugs.
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To the Editor:
urning mouth syndrome (BMS), also
known as glossodynia or stomatodynia,
is characterized by burning oral pain in the
absence of an identifiable lesion.1 The
prevalence of BMS is estimated to be between 0.7% and 4.5%.2–4 This condition
is more common in postmenopausal women5
and often co-occurs with other symptoms,
such as parageusia and xerostomia.4
There are no laboratory tests to establish a definitive diagnosis of BMS.6 As
BMS is associated with somatization, anxiety, depression, dissociation, and personality disorders,7,8 a patient's description of these
symptoms may be overlooked. Herein, we
present the case of a patient with bipolar disorder who developed BMS after the initiation
of quetiapine.

B

CASE PRESENTATION
The patient is a 65-year-old White woman
with a longstanding history of bipolar 1 disorder with mixed features. The patient's
symptoms were relatively controlled with
10-mg aripiprazole and 0.25-mg clonazepam
daily. In May 2020, she reported increasing
jaw tightness, and therefore, aripiprazole was
cross-titrated with quetiapine. Concurrently, clonazepam was discontinued. By June 2020, the
cross-titration was completed, and she was no
longer taking aripiprazole, which was replaced with 300-mg quetiapine nightly. She
reported resolution of her facial extrapyramidal symptoms and denied any adverse effects from quetiapine.
www.psychopharmacology.com
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Throughout July 2020, she began to
experience worsening xerostomia. She used
sugarless gum and lemon drops/mints, but
these did not alleviate symptoms. At this
time, she demonstrated a weakly positive
antinuclear antibody titer of 1:320. By
August 2020, her symptoms had significantly intensified; she reported a constant
burning sensation on her hard palate accompanied by a sore throat. The symptoms
were severe enough to cause her distress
during the day and interfere with sleep.
Subsequently, the patient underwent
an extensive medical workup. Electrolytes
were within normal limits, as were renal
and liver functions. Anti–Sjögren syndrome A/anti–Sjögren syndrome B, anti–
double-stranded DNA, C3 and C4 complement, and extractable nuclear antigen/
anti-Smith/antiribonucleoprotein antibodies
were all negative. Complete blood cell count
with differential, iron level, and hemoglobin/
hematocrit level were within normal limits.
Biopsy of her lip showed squamous mucosa,
and biopsy of minor salivary gland showed
focal fibrosis, focal atrophy, and minimal
chronic inflammation. The focus score of 0
to 4 mm2 was not consistent with Sjögren
syndrome.9,10
Considering her negative medical
workup, we suspected that she developed
BMS secondary to quetiapine. In October
2020, quetiapine was cross-titrated with
olanzapine over 4 weeks. Subsequently, while
on olanzapine 5 mg daily, her BMS fully resolved by December 2020. She continued to
report occasional xerostomia, which she differentiated from BMS.

AUTHOR DISCLOSURE
INFORMATION
The authors declare no conflicts of
interest.
Patient's verbal consent was obtained
to develop and to publish this case report.
Information has been deidentified to protect anonymity.
Received January 8, 2021; accepted after
revision March 25, 2021.

DISCUSSION
The exact etiology and pathogenesis of primary BMS have not been well delineated.1
It has, however, been linked with central
and peripheral neuropathic disturbances,
including dopamine pathway dysfunction.5
Specifically, patients with BMS demonstrate disruption in striatal dopamine regulation.11,12 Local and systemic factors,
including autoimmune diseases, nutritional
deficits, infections, and medications, may
contribute to the development of secondary
BMS.8 Medications that have been implicated in BMS include angiotensin-converting
enzyme inhibitors, efavirenz, fluoxetine,
L-thyroxine, levodopa, nevirapine, sertraline, and topiramate among others.3,8,13,14
Our patient's symptoms remitted after
quetiapine was discontinued. Quetiapine's
mechanism of action is through blockade
of dopamine D2 and serotonin 5HT2A receptors; it also has serotonin 5HT1A partial
agonistic, serotonin 5HT2C and 5HT7
antagonist, histamine H1 antagonist, M1
antimuscarinic, and α1 adrenergic antagonist
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properties.15 One, or multiple, such receptor modulations may be implicated.
Although we speculate that our patient's
symptoms were caused by quetiapine, she
may have already had BMS before
quetiapine's initiation—she was previously
taking clonazepam and aripiprazole, both
of which have been cited in the improvement of BMS symptoms.6,16–18 Moreover,
BMS is a diagnosis of exclusion, and we
felt that our patient's negative medical workup
was sufficient to explain her diagnosis.
However, a variety of local and systemic
disorders may mimic BMS symptoms,5
which potentially may have confounded her
presentation. There may also exist some correlations between iron deficiency states and BMS4;
however, our patient's iron level was normal.
To the best of our knowledge, there
are no other reported cases of BMS secondary to quetiapine. Although our patient responded well to olanzapine as has been
described previously,19 treatment options
for BMS are limited and are largely based
on cessation of the presumed offending
agents. Further literature on psychopathological explanations for BMS, along with
randomized controlled trials for potential
therapeutics, would be welcomed contributions.
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